It is estimated that around 80% of innovator companies rely on external companion diagnostic developers, mostly owing to the lack of the required in-house expertise. On the other hand, there are numerous contract service providers, offering vast portfolios of services for diagnostic test / assay development. Such companies are known to possess extensive technical knowledge, and experience in working with cutting-edge analytical tools and technologies, such as in situ hybridization (ISH), immunohistochemistry (IHC), next generation sequencing (NGS), polymerase chain reaction (PCR).
To order this 320+ page report, which features 120+ figures and 115+ tables, please visit this link
The USD 800+ million (by 2030) financial opportunity within the companion diagnostics development services market has been analysed across the following segments:
- Type of Service Offered
- Feasibility Studies
- Assay Development
- Analytical Validation
- Clinical Validation
- Type of Assay Technique Used
- in situ hybridization / Immunohistochemistry
- Next Generation Sequencing
- Polymerase Chain Reaction
- Others
- Key geographical regions
- North America
- Europe
- Asia Pacific
The report features inputs from eminent industry stakeholders, according to whom the development of companion diagnostics is largely outsourced, owing to the exorbitant costs associated with the setting-up of in-house expertise / capabilities. The report includes detailed transcripts of discussions held with the following experts:
- Anton Iliuk (President and Chief Technology Officer, Tymora Analytica)
- Paul Kortschak (Senior Vice President, Novodiax)
- Pablo Ortiz (Chief Executive officer, OWL Metabolomics)
- Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories)
Table of Contents
- Preface
2. Executive Summary
Introduction - Market Landscape
- Company Profiles
- Partnerships and Collaborations
- Likely Partner Analysis
- Company Competitiveness Analysis
- Stakeholder Needs Analysis
- Value Chain Analysis
- Clinical Research on Cancer Biomarkers: Big Pharma Perspective
- Market Forecast And Opportunity Analysis
- Executive Insights
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
